MarketResearchReports.biz has recently announced the addition of a market study “ EpiCast Report: Schizophrenia – Epidemiology Forecast to 2025”, is a comparative analysis of the global market.
Schizophrenia is a severe mental disorder that affects an individuals behaviors, thoughts, and emotions; it is extremely heterogeneous, and no two affected individuals will have the same experience. The disorder is characterized by the presence of positive and negative symptoms. Positive symptoms can be defined as behaviors that are not usually seen in healthy individuals; these symptoms tend to be of a psychotic nature and include hallucinations and delusions. Negative symptoms, on the other hand, are described as a reduction in normal behaviors. People with schizophrenia who exhibit negative symptoms show a lack of motivation, emotions, or interest (apathy), and may sometimes refuse to speak (mute). The severity of these symptoms varies with each affected individual.
GlobalData epidemiologists forecast that the 12-month diagnosed prevalent cases of schizophrenia in the 7MM will increase from 3,298,475 cases in 2015 to 3,462,096 cases in 2025 at an Annual Growth Rate (AGR) of 0.50%. The US has the highest number of 12-month diagnosed prevalent cases of schizophrenia among the individual markets of the 7MM throughout the forecast period, with 1,738,862 cases in 2015 and 1,897,801 cases in 2025, accounting for over 50% of cases in the 7MM.
GlobalData epidemiologists utilized comprehensive, country-specific data from peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the 12-month diagnosed prevalent cases of schizophrenia. Furthermore, GlobalData conducted PMR for schizophrenia in all of the 7MM to both overcome shortcomings of the available literature and better aid market-specific forecasting of schizophrenia. Throughout the 7MM, schizophrenia cases were segmented by age and sex, allowing for a comprehensive, detailed forecast of age- and sex-specific schizophrenia to 2025.
Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/879217
– The Schizophrenia EpiCast Report provides an overview of the risk factors and global trends of schizophrenia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for 12-month diagnosed prevalent cases of schizophrenia segmented by sex and age in these markets.
– The schizophrenia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Schizophrenia EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
– Quantify patient populations in the global schizophrenia market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for schizophrenia therapeutics in each of the markets covered.
Table Of Content
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Epidemiology 7
2.1 Disease Background 7
2.2 Risk Factors and Comorbidities 8
2.3 Global Trends 10
2.3.1 US 11
2.3.2 5EU 12
2.3.3 Japan 13
2.4 Forecast Methodology 14
2.4.1 Sources Used 15
2.4.2 Forecast Assumptions and Methods 16
2.4.3 Sources Not Used 23
2.5 Epidemiological Forecast for Schizophrenia (2015-2025) 24
2.5.1 12-Month Diagnosed Prevalent Cases of Schizophrenia 24
2.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 25
2.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 27
2.5.4 Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia 29
2.6 Discussion 30
2.6.1 Epidemiological Forecast Insight 30
2.6.2 Limitations of the Analysis 30
2.6.3 Strengths of the Analysis 31
3 Appendix 32
3.1 Bibliography 32
3.2 Physicians and Specialists Included in This Study 37
3.2.1 Primary Research – Key Opinion Leaders Interviewed for this Report 37
3.2.2 Primary Research – Prescriber Survey 39
3.3 About the Authors 40
3.3.1 Epidemiologist 40
3.3.2 Reviewers 40
3.3.3 Global Director of Therapy Analysis and Epidemiology 42
3.4 About GlobalData 43
3.5 About EpiCast 43
3.6 Disclaimer 44